熱門資訊> 正文

KalVista Pharmaceuticals GAAP每股收益为-1.12美元，亏损0.17美元，收入为143万美元，亏损0.66万美元

2025-09-11 19:03

KalVista Pharmaceuticals press release (NASDAQ:KALV): Q1 GAAP EPS of -$1.12 misses by $0.17.
Revenue of $1.43M misses by $0.66M.
As of July 31, 2025, the Company had cash, cash equivalents and marketable securities of approximately $191.5 million.

More on KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc. (KALV) Presents At Cantor Global Healthcare Conference 2025 Transcript
KalVista Pharmaceuticals Ekterly Faces A Shrinking Market And Oral Competitor Threat (Downgrade)
KalVista: FDA Approval Of EKTERLY As Oral On-Demand HAE Drug Is Just Beginning
KalVista, Biogen, Ionis get EU positive opinions for key drugs
KalVista Pharmaceuticals rises after FDA nod for Ekterly

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。